Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 64 Publications

12 Customer Reviews

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

    Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NGi5bnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHyRotjPzJiaB?= MnrtSG1UVw>? NEGzW49KSzVyPUCuNFAxODdizszN NY\UNGVKOTd7NU[wPFA>
K562 NV\xPXZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXW3NkBp MlP6SG1UVw>? M4nubGlEPTB;MD6wNFEh|ryP NGfqZ|YyPzl3NkC4NC=>
M07e NEK3cnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXG3NkBp NInVUHpFVVOR NVT4RnQ3UUN3ME2wMlAxOTJizszN MUSxO|k2PjB6MB?=
ALL3 MXrDfZRwfG:6aXOgRZN{[Xl? MV:wMlHPxE1? MkXKO|IhcA>? MoPISG1UVw>? MnHITWM2OD1yLkCwNFQh|ryP M2LiW|E6QDh7NUSw
CML MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHETGZ1OjBibXnu NWnsZVM{TE2VTx?= NF:xT5VKSzVyPUCuNFAyKM7:TR?= MlzhNVkzOTlyMU[=
BA/F3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTMO|IhcA>? NUHQPGZ1TE2VTx?= MnvtTWM2OD14LkW4PUDPxE1? NIX0PZMzOzB6OE[0OC=>
BA/F3 M3fhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHQO|IhcA>? M1vwW2ROW09? MUTJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?= NWTIe3FmOjNyOEi2OFQ>
BA/F3 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzJTG04OiCq NGfOUoxFVVOR NVvHbZJoUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?= Mm\rNlMxQDh4NES=
BA/F3 M4jZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:wO|IhcA>? NYjWZYpbTE2VTx?= MkTkTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryP M{nlVlI{ODh6NkS0
BA/F3 MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUiwdHY1PzJiaB?= NI\0RoZFVVOR NXzVSJNVUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRkS4OnMhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxODoQvF2= NHnK[owzOzNyMUewNy=>
BA/F3 NV3qb5loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr0O|IhcA>? M4nHTmROW09? NUfLfYlyUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUK1OWshdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOzMQvF2= NUfTTpNqOjN|MEG3NFM>
BA/F3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HNcVczKGh? MULEUXNQ NIrNTHhKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA2Oc7:TR?= NH3hc3ozOzNyMUewNy=>
BA/F3 NV36XIg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm0foU4OiCq NYjhbGd[TE2VTx?= MVLJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO MYWyN|MxOTdyMx?=
BA/F3 M1fod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvmcJg4OiCq NUnHc3lPTE2VTx?= NI\6d4dKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAyO87:TR?= M3m5OVI{OzBzN{Cz
BA/F3 NUOze3hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG3NkBp MXLEUXNQ M1fwUmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQlPSMWFDVCCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yMEG5{txO NYLObJdpOjN|MEG3NFM>
BA/F3 MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLYO|IhcA>? NUTuOmoxTE2VTx?= M3jlR2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFl{NUPIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFI{|ryP MkfZNlM{ODF5MEO=
BA/F3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXraRWRCPzJiaB?= NUmzNpliTE2VTx?= MlrHTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB|LkdOwG0> MWiyN|MxOTdyMx?=
BA/F3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHhNZZCPzJiaB?= M4K0dmROW09? MlHNTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP NWnMO|FXOjN|MEG3NFM>
T cell M1LXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVm3NkBp MnPJSG1UVw>? M4DJNWlvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO M1nWV|E4OTV2NUGy
WiDr NFPi[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLMSlRTPzJiaB?= NF;q[plFVVOR NY\NUI9qUUN3ME2wMlA2OiEQvF2= NGHoSHgyPTZzNUWxNi=>
PC3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzRO|IhcA>? MmO4SG1UVw>? M333OmlEPTB;MD6wNFk1KM7:TR?= MlHJNVU3OTV3MUK=
MDA-MB-231 M33KWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUm3NkBp MkHvSG1UVw>? NE\JbnVKSzVyPUCuNFEzKM7:TR?= NH7yVIsyPTZzNUWxNi=>
Hs578T MVnDfZRwfG:6aXOgRZN{[Xl? MXq3NkBp MWnEUXNQ MXHHTVUxRTBwMEOg{txO M3G0[lI1ODF3M{K3
HMEC MV7DfZRwfG:6aXOgRZN{[Xl? NF7xe|c4OiCq M3n4bWROW09? MmrQS2k2OD1zLkig{txO MUiyOFAyPTN{Nx?=
DU145 MUHDfZRwfG:6aXOgRZN{[Xl? M4jOWlczKGh? Moj5SG1UVw>? M13zdGdKPTB;MD6xOkDPxE1? NXHnfW5qOjRyMUWzNlc>
U251 MYXDfZRwfG:6aXOgRZN{[Xl? M{L6blczKGh? M3z4bGROW09? NYnnT2VGT0l3ME2yMlgyKM7:TR?= MoPsNlQxOTV|Mke=
NCI60 MlfIR5l1d3SxeHnjJGF{e2G7 M2jMRVczKGh? M2CwRWROW09? MVnHTVUxRTVwNzFOwG0> NWDnOYVXOjRyMUWzNlc>
MALME-3M NGLvVXlEgXSxdH;4bYMhSXO|YYm= NV;XPFhYPzJiaB?= NIfa[ZhFVVOR M1jiTWdKPTB;Nj62NUDPxE1? NGXYZ3czPDBzNUOyOy=>
KM12 MX3DfZRwfG:6aXOgRZN{[Xl? MmPUO|IhcA>? NUSwV4dRTE2VTx?= MWLHTVUxRTdwNESg{txO NUnP[5VNOjRyMUWzNlc>
SW620 M3[0cGN6fG:2b4jpZ{BCe3OjeR?= NGS3N2o4OiCq MoPzSG1UVw>? Mk\aS2k2OD16LkSzJO69VQ>? NUXvS3U3OjRyMUWzNlc>
RXF 393NL Mon2R5l1d3SxeHnjJGF{e2G7 MnzqOEBl[Xm| NV\JeIdFTE2VTx?= MXfJR|UxRTBwMEKxO{DPxE1? NUP2OI9JOjN{NUOwO|Q>
LXFA 983L M4fTRWN6fG:2b4jpZ{BCe3OjeR?= M4HabFQh\GG7cx?= NUnNcFJnTE2VTx?= Mm\QTWM2OD1yLkC1OlUh|ryP NE\VT2wzOzJ3M{C3OC=>
PRXF DU145 NGHReVlEgXSxdH;4bYMhSXO|YYm= MUC0JIRigXN? MUnEUXNQ MWTJR|UxRTBwME[yN{DPxE1? MlTLNlMzPTNyN{S=
PAXF 1657L M{DYUmN6fG:2b4jpZ{BCe3OjeR?= MnXOOEBl[Xm| NXnHfpB1TE2VTx?= MlOzTWM2OD1yLkGyNUDPxE1? NHPkRoQzOzJ3M{C3OC=>
CXF 1103L NI\yZ3VEgXSxdH;4bYMhSXO|YYm= NUjNZld5PCCmYYnz NFvGVFZFVVOR MmHvTWM2OD12LkO2JO69VQ>? NELKXYkzOzJ3M{C3OC=>
GXF251L NIDkO3dEgXSxdH;4bYMhSXO|YYm= NYrLbm5KPCCmYYnz MkfUSG1UVw>? NEjmWYdKSzVyPUKuNlUh|ryP NYDMcmJ4OjN{NUOwO|Q>
NCI-H23 NVfKVnZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK5O|IhcA>? M4PxO2ROW09? M{LyRWlEPTB;Mj6yO{DPxE1? NHPDRpQzOzV{MUCyNC=>
HCT116 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\LfVQ4OiCq M3PMeWROW09? NYHVR2k5UUN3ME2yMlMh|ryP MX:yN|UzOTB{MB?=
MCF7 MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjDc3A4OiCq NHTqS2NFVVOR M2DPOWlEPTB;Mj61O{DPxE1? NHH5[5QzOzV{MUCyNC=>
NCI-H460 M1q5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO5O|IhcA>? MkPLSG1UVw>? NWfRPI5CUUN3ME24Mlk6KM7:TR?= M332OFI{PTJzMEKw
DLD1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXO3NkBp NX[5dZk{TE2VTx?= MVvJR|UxRTRwNjFOwG0> NUfQfmRuOjN3Nke5OlA>
NCI-H661 NF[2RVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XtSVczKGh? NVfsXY5TTE2VTx?= M1fwemlEPTB;Nz64JO69VQ>? MkPzNlM2Pjd7NkC=
A549 NWrySJBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK3e|ZZPzJiaB?= NHfrUo5FVVOR M13lOmlEPTB;OD6yJO69VQ>? M2qzPFI{PTZ5OU[w
U937 NIDESJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITQOYw4OiCq M4LYPGROW09? M1LwU2lEPTB;MUKuNkDPxE1? NEPXOlQzOzV4N{m2NC=>
HEK293 MknmSpVv[3Srb36gRZN{[Xl? NGHJXXQyOMLizszN MmG4SG1UVw>? MnnXTY5lfWOnczDibY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIH\1cIwudGWwZ4ToJGhqey22YXfn[YQhVXm2MTDrbY5ie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC5aYToJGlEPTBib3[gNE4xPjQQvF2= Ml;nNlI4PzB4MUC=
HUVEC Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrSOmI4OC5zNdMg{txO NGHqfZQ4OiCq MXrEUXNQ NYDwb24{UW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBifCByLkG1JJVO NXPkRZd6OjJ6NUO5PVM>
HUVEC M3\NdGZ2dmO2aX;uJGF{e2G7 MXexOeKh|ryP NFvv[Jo4OiCq M3yzdGROW09? NGDLT3dKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIH7leJdwemtiZn;ycYF1cW:wIHH0JFEvQCC2bzCxOUB2VQ>? NHrZTngzOjh3M{m5Ny=>
Plasmodium falciparum M{j1emZ2dmO2aX;uJGF{e2G7 NH72ZpQyOMLizszN M4PPNVE2KG2rbh?= M{HnfWROW09? NVj0VlA6UW6qaXLpeJMhWGyjc33v[Il2dSCoYXzjbZBienWvIIDyc4xq\mW{YYTpc44h[nliaX7obYJqfGmwZzD0bIUhTnWwY4Tpc44hd2ZiUH\DSHBMOSCycn;0[YlvKHerdHigTWM2OCCxZjCxMlE4|ryP NHmyRm8zPDV3MEOzNC=>
PC3 MkXxSpVv[3Srb36gRZN{[Xl? M2T5UVAvOSEQvF2= MoCwOUBp MlTxSG1UVw>? MYXJcohq[mm2czDoeY1idiCSQ{OgZ4VtdCCjZHjld4lwdiCjdDCxNFAhdk1? MUWxPVQ3Ojl5NR?=
DU145 MojWSpVv[3Srb36gRZN{[Xl? MViwMlEh|ryP NInxemw2KGh? MVXEUXNQ NE\GcohKdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW|aX;uJIF1KDFyMDDuUS=> M2ezbVE6PDZ{OUe1
PC3 NHPSfHRMcW6jc3WgRZN{[Xl? MlryNE4yKM7:TR?= NUX4ZpNpPSCq NEPxblBFVVOR Mo\VTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?= NYLhPY5COTl2NkK5O|U>
DU145 NEfWV3BMcW6jc3WgRZN{[Xl? NYnsdVZDOC5zIN88US=> MlrOOUBp Ml7BSG1UVw>? MYLJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2= NYOzXFdGOTl2NkK5O|U>
PC3 MmHsT4lv[XOnIFHzd4F6 MWqwMlEh|ryP NFLHWXI2KGh? NX[5c4U4TE2VTx?= MVnJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> NHrNWJoyQTR4Mkm3OS=>
DU145 MYHLbY5ie2ViQYPzZZk> MmD4NE4yKM7:TR?= MXG1JIg> NY\2T4NRTE2VTx?= NGfIbHpKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?= MYixPVQ3Ojl5NR?=
Huh7 MkSxRY51cX[rcnHsJGF{e2G7 Mn65Nk42KM7:TR?= NIrySVg1KGSjeYO= NW\m[ZNMTE2VTx?= NE[5[JpKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2= NVHVSos1OTd|NkC2O|Y>
C6/36 NY\VUG9MSW62aY\pdoFtKEG|c3H5 NHvJVlAzNjVizszN NF\3WIQ1KGSjeYO= MlTuSG1UVw>? NWTkZXFbUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCjc3nhckB1cWencjDtc5NyfWm2bzDDOk8{PiClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= NHjTbVYyPzN4ME[3Oi=>
U937 NV70XJZITnWwY4Tpc44hSXO|YYm= M3\PZlEh|ryP M4X2dFEhcA>? Mn\KSG1UVw>? MnjMVoVlfWOnczDiZZNidCCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? NVnqV5JDOTd4OESwPVk>
U937 M1HXb2Z2dmO2aX;uJGF{e2G7 MlHONUDPxE1? NWTnSZBvOSCq MmXpSG1UVw>? M4rsTnJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{ NFP3VGgyPzZ6NEC5PS=>
murine mast cell M2LGSGZ2dmO2aX;uJGF{e2G7 NWnVUIhFOSEQvF2= NFSyV2UzPCCq MWPEUXNQ M4D1ZWlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP M2TwXVE4Pjh2MEm5
BV-173 NXrrTJVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzUOZVKSzVyPUCuNFAxODByMUC5JO69VQ>? MojvV2FPT0WU
K-562 NX;WUHZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLwTWM2OD1yLkCwNFAxODJ4NjFOwG0> NHnObWxUSU6JRWK=
BL-70 M4Pu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnuSWtQUUN3ME2wMlAxODByMEiyNkDPxE1? M3TPUXNCVkeHUh?=
EM-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMECwNFAyODhizszN M1\rbnNCVkeHUh?=
LAMA-84 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu1c|hKSzVyPUCuNFAxODB|MkGg{txO MVHTRW5ITVJ?
MEG-01 MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMECwNFA6QCEQvF2= M1LTSXNCVkeHUh?=
EoL-1-cell NFqzXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fW[GlEPTB;MD6wNFAxOTNzIN88US=> NV3TelJWW0GQR1XS
CTV-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMECwNFQxPCEQvF2= MX\TRW5ITVJ?
TE-15 NV;OZZYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMEC1PFkh|ryP MYHTRW5ITVJ?
NOS-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv0bXQ5UUN3ME2wMlAxPjF|IN88US=> M3;uTXNCVkeHUh?=
D-336MG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj1TWM2OD1yLkCwOlMh|ryP MWfTRW5ITVJ?
LB1047-RCC MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXBTWM2OD1yLkCwPVg6KM7:TR?= M3znVHNCVkeHUh?=
LB996-RCC NFrGcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMEC5PVEh|ryP Mn;XV2FPT0WU
SW982 NYPZRppTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfxTWM2OD1yLkCxNVE2KM7:TR?= M4PvN3NCVkeHUh?=
TK10 M{PqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[wflVjUUN3ME2wMlAyOTd2IN88US=> M4fsUnNCVkeHUh?=
A704 NG[xOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEG0PVEh|ryP MlnIV2FPT0WU
TE-8 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMEG1O|Yh|ryP M3XDdHNCVkeHUh?=
DOHH-2 NF\Cb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1m2emlEPTB;MD6wNVcyQSEQvF2= M2K1WXNCVkeHUh?=
HOP-62 Ml3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInEUGJKSzVyPUCuNFE5OzRizszN NVK5[Y9kW0GQR1XS
TE-12 NYDETGNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rNUGlEPTB;MD6wNVg3OSEQvF2= NXnuOpBnW0GQR1XS
KGN MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPiOWdrUUN3ME2wMlAyQTR{IN88US=> NVXVPJhbW0GQR1XS
NCI-H1648 NWLpVZB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[xTWM2OD1yLkCyNFEyKM7:TR?= MUfTRW5ITVJ?
OS-RC-2 NVHlS4Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwMEKwN{DPxE1? MX3TRW5ITVJ?
GB-1 M2PEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPZeFJKSzVyPUCuNFIyPTdizszN Mmn5V2FPT0WU
RXF393 NIDBOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzqTWM2OD1yLkCyN|U4KM7:TR?= NInyZZRUSU6JRWK=
LC-2-ad NHjHVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\FTWM2OD1yLkCyOVg3KM7:TR?= MWrTRW5ITVJ?
KS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXjNVFVUUN3ME2wMlAzPzNizszN NEPBO2ZUSU6JRWK=
ETK-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEK4N|Ih|ryP M2\W[3NCVkeHUh?=
SW954 NV;2OmFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMEK5Nlch|ryP NWPDelFrW0GQR1XS
Becker MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMEOwNFMh|ryP M1;ob3NCVkeHUh?=
MZ1-PC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMEOxNVkh|ryP MVzTRW5ITVJ?
ES6 NVjjbWdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ruRWlEPTB;MD6wN|E6OyEQvF2= MUfTRW5ITVJ?
KURAMOCHI NVriUVVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\oS2lEPTB;MD6wN|Q5PyEQvF2= NFPtcWFUSU6JRWK=
CGTH-W-1 M{W5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nyPWlEPTB;MD6wN|U1QCEQvF2= NFjySVZUSU6JRWK=
VA-ES-BJ NWW0ZVVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r4cGlEPTB;MD6wN|kxOiEQvF2= NHfzRndUSU6JRWK=
LXF-289 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPqSHVKSzVyPUCuNFM6PTZizszN M1vWWXNCVkeHUh?=
MPP-89 M1W2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDZTFVKSzVyPUCuNFQxPDlizszN MWjTRW5ITVJ?
SW872 NUXiSHg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMESxOlEh|ryP Mli4V2FPT0WU
SNB75 MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\BWWVVUUN3ME2wMlA1PDN3IN88US=> MWPTRW5ITVJ?
PSN1 M2DReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMES0O|Qh|ryP NGrNNmdUSU6JRWK=
LB831-BLC MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK2d4tKSzVyPUCuNFQ3ODlizszN NV7U[nl[W0GQR1XS
MFH-ino MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjMTWM2OD1yLkC0O|I1KM7:TR?= NUP3eGc5W0GQR1XS
TGBC24TKB M13JZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMES3OlEh|ryP MWjTRW5ITVJ?
A388 M3LPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK1TWM2OD1yLkC1NFk2KM7:TR?= NWKxbopmW0GQR1XS
BB30-HNC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPrTWM2OD1yLkC1OFM4KM7:TR?= MlXZV2FPT0WU
GI-ME-N M332e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnm[ItKSzVyPUCuNFYyOThizszN M2i0cnNCVkeHUh?=
TGBC1TKB MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\WNo17UUN3ME2wMlA3OTZ2IN88US=> M3TwNXNCVkeHUh?=
TE-10 M3rXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j2[2lEPTB;MD6wOlM2PyEQvF2= NILlVIZUSU6JRWK=
A498 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMEeyPFQh|ryP NFXlRpJUSU6JRWK=
TE-11 MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uzU2lEPTB;MD6wO|g2QCEQvF2= NEDPWHZUSU6JRWK=
BB65-RCC NYfhOoljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnuxTWM2OD1yLkC4NlI4KM7:TR?= Ml3sV2FPT0WU
C2BBe1 NV3GdGxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLyVYFKSzVyPUCuNFg{ODhizszN NWLtPIV6W0GQR1XS
NCI-H747 M13ZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r4Z2lEPTB;MD6wPFM3OiEQvF2= MY\TRW5ITVJ?
IST-MES1 NIHqSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEi1OVIh|ryP MlXGV2FPT0WU
KALS-1 NVfGdFdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMEm0PUDPxE1? NX\UV2o3W0GQR1XS
GCIY NGDKNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvUbopKSzVyPUCuNFk3PTZizszN M2HMfHNCVkeHUh?=
RL95-2 NXnOcmM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn6bpNRUUN3ME2wMlExOzhizszN MlT3V2FPT0WU
TE-1 NXXxbG5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvROHg1UUN3ME2wMlExPTRizszN M3SzdXNCVkeHUh?=
NCI-H1355 MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jWUGlEPTB;MD6xNVAzQCEQvF2= M2jheXNCVkeHUh?=
SW962 NFXs[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\zSGpJUUN3ME2wMlEyOjl{IN88US=> Mm\NV2FPT0WU
KLE MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfHTWM2OD1yLkGxN|E4KM7:TR?= MX;TRW5ITVJ?
MC116 NVHIdZJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPYTWM2OD1yLkGxOFEh|ryP M1rjO3NCVkeHUh?=
NMC-G1 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXVTWM2OD1yLkGxOlA3KM7:TR?= NFrpWFhUSU6JRWK=
KU812 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMUG4PFMh|ryP MXnTRW5ITVJ?
COLO-829 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fVT2lEPTB;MD6xNlIyOyEQvF2= NUTTZmZDW0GQR1XS
NTERA-S-cl-D1 NFXpRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHixW|lKSzVyPUCuNVIzQDNizszN M4XvdXNCVkeHUh?=
IST-MEL1 NV[yZnBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPFfJF5UUN3ME2wMlE{PDVizszN M1zHZ3NCVkeHUh?=
MLMA MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT5fmo5UUN3ME2wMlE1ODN{IN88US=> M13tOHNCVkeHUh?=
LS-123 NHvMbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlToTWM2OD1yLkG0NFY1KM7:TR?= NYe3RXpoW0GQR1XS
LB2518-MEL NIH6R|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPXfZlKSzVyPUCuNVQyPjJizszN NFfGPIhUSU6JRWK=
NB69 MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfJTnZKSzVyPUCuNVQ1OzZizszN NWPSXoFCW0GQR1XS
8-MG-BA M1PUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD5dolZUUN3ME2wMlE2PDV6IN88US=> M1vETnNCVkeHUh?=
K5 MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMU[0PFkh|ryP NVjQcFZjW0GQR1XS
KINGS-1 MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLHRpFKSzVyPUCuNVY3PjZizszN MljMV2FPT0WU
SF268 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\aNnVJUUN3ME2wMlE4PDB2IN88US=> NFn0VYNUSU6JRWK=
PF-382 M32zXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMUe2O|gh|ryP M3vFVHNCVkeHUh?=
SH-4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMUi0NVMh|ryP MULTRW5ITVJ?
NALM-6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMUmyPVUh|ryP NFTuOVJUSU6JRWK=
CP66-MEL NVrTcI95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTKTWM2OD1yLkG5OVMyKM7:TR?= NVz5V29PW0GQR1XS
697 M3PxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjo[FlCUUN3ME2wMlE6QTh5IN88US=> NX;kRWZuW0GQR1XS
CP67-MEL MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT0c5lKSzVyPUCuNlA1QDhizszN NWD4OHduW0GQR1XS
DSH1 NHXUWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWzTWM2OD1yLkK0NFAyKM7:TR?= Mk[3V2FPT0WU
HCE-4 M2rGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;HUlVKSzVyPUCuNlY1OzlizszN NVrHOYJOW0GQR1XS
MZ2-MEL M4X2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne2TWM2OD1yLkK4OVM4KM7:TR?= MV;TRW5ITVJ?
BL-41 M3LsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTETWM2OD1yLkK5NVI{KM7:TR?= NHHiXWlUSU6JRWK=
HUTU-80 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjrTWM2OD1yLkOxOFIh|ryP MXnTRW5ITVJ?
LOXIMVI MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M163VmlEPTB;MD6zNVUxOyEQvF2= MYrTRW5ITVJ?
no-10 M2rxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTBfmZ4UUN3ME2wMlMyQTNzIN88US=> NWDYXWNuW0GQR1XS
KARPAS-422 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwM{O5PVch|ryP M4rUdHNCVkeHUh?=
SW684 NF7uR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLPVm9OUUN3ME2wMlM1QThizszN MYDTRW5ITVJ?
SF126 Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwM{W0NUDPxE1? MUDTRW5ITVJ?
D-263MG NYjFNWpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fId2lEPTB;MD6zOlIzPCEQvF2= MYXTRW5ITVJ?
OVCAR-4 MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDZSZkxUUN3ME2wMlM4PDN|IN88US=> MW\TRW5ITVJ?
BB49-HNC NVPKTVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITOOVhKSzVyPUCuN|g2QTlizszN MXnTRW5ITVJ?
ONS-76 M1LLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fEVGlEPTB;MD60Nlk2OSEQvF2= NYi2PFh7W0GQR1XS
MZ7-mel NIPESZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe1RYtmUUN3ME2wMlQ4QTFzIN88US=> M1nu[XNCVkeHUh?=
RCC10RGB MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XkTWlEPTB;MD60PVEyKM7:TR?= MlzVV2FPT0WU
BOKU M3qxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4m5NmlEPTB;MD60PVE{OyEQvF2= M2DWcXNCVkeHUh?=
no-11 NU\w[IJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[0R4hKSzVyPUCuOVAzOjhizszN M1zIWnNCVkeHUh?=
IST-SL2 NIjUWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorhTWM2OD1yLkWwN|AzKM7:TR?= NEPS[4hUSU6JRWK=
RKO MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2e5fGlEPTB;MD61Nlk3PiEQvF2= Mn\xV2FPT0WU
HT-144 NWiyPWhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwNUO2NFkh|ryP NW[yc5BQW0GQR1XS
NCI-H446 NIi0RpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELQXnpKSzVyPUCuOlI4PiEQvF2= NYTzRZJEW0GQR1XS
QIMR-WIL NE\pdWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\JXmlEPTB;MD63NFYzQSEQvF2= NFS3VVJUSU6JRWK=
MHH-PREB-1 Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n1OGlEPTB;MD63OFQ3QSEQvF2= M2n0XXNCVkeHUh?=
EW-16 NHvsfXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPRTZhKSzVyPUCuO|YyPzhizszN NGrkRphUSU6JRWK=
EW-24 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPSb49KSzVyPUCuO|gyPjVizszN NYmyXVh5W0GQR1XS
LB373-MEL-D NYnwTZN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwOEK1NFgh|ryP NWmyfVF4W0GQR1XS
TE-9 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCxXo9KSzVyPUCuPFc2OzJizszN M4r6RnNCVkeHUh?=
A3-KAW MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO0RoNKSzVyPUCuPVg1PTJizszN M2jiXHNCVkeHUh?=
A101D MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;hW4JKSzVyPUGuNFMxPDNizszN NX7obWl5W0GQR1XS
OCUB-M M4r0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFwMES0NVIh|ryP M4i2b3NCVkeHUh?=
ES4 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3GTWM2OD1zLkC1NVQ2KM7:TR?= MUXTRW5ITVJ?
TE-6 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e3dWlEPTB;MT6yNVIzPiEQvF2= MoT1V2FPT0WU
D-502MG NWfWVXdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\lW5lUUUN3ME2xMlI{Ozd4IN88US=> MYjTRW5ITVJ?
KNS-42 Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;DZYJKSzVyPUGuNlQ1OTJizszN NFXh[5BUSU6JRWK=
SNU-C2B NXLyeJU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwM{C1PFkh|ryP NFPodWNUSU6JRWK=
NCI-H1838 NYf5Z3RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDJbYFKSzVyPUGuN|A4OzNizszN NY\5bpllW0GQR1XS
NKM-1 M{S4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXtTWM2OD1zLkOwPFU6KM7:TR?= MofnV2FPT0WU
GI-1 MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ziZ2lEPTB;MT6zOlIzKM7:TR?= Ml\hV2FPT0WU
NB5 NIDHfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT0TWM2OD1zLkO5PFI4KM7:TR?= NYjIXXhoW0GQR1XS
CAS-1 NX\1dXhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX6[nIyUUN3ME2xMlQxQTl{IN88US=> NWPJeWV4W0GQR1XS
HCE-T M360OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjuTWM2OD1zLkW2O|E1KM7:TR?= M1fW[nNCVkeHUh?=
SBC-1 NFnN[|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zGXWlEPTB;MT61O|k5PCEQvF2= MnK0V2FPT0WU
JiyoyeP-2003 MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwN{O0OlYh|ryP NX\rPVlpW0GQR1XS
TE-5 NFzHZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwN{mxN|kh|ryP M1;hbnNCVkeHUh?=
CAN MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XaNGlEPTB;MT64NlI2OiEQvF2= M4rjPHNCVkeHUh?=
SK-UT-1 M1\UUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHye4VKSzVyPUKuNVY3QTNizszN NVrQS2JRW0GQR1XS
JVM-2 NV;5WZdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;BdHl5UUN3ME2yMlM3Ojh2IN88US=> NWXaSZJCW0GQR1XS
LB771-HNC MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vzWmlEPTB;Mj61O|U2OSEQvF2= M3fxPHNCVkeHUh?=
NCCIT MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfrWHdKSzVyPUKuPFY3OTZizszN M{XsfXNCVkeHUh?=
NCI-H2126 NHXsc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnMWox3UUN3ME2yMlg4PTV{IN88US=> M1q3fnNCVkeHUh?=
Calu-6 NUDlfYtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33CO2lEPTB;Mz6wOVc1OSEQvF2= NEDyXIJUSU6JRWK=
SK-LMS-1 MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ToRmlEPTB;Mz6xNVg5PiEQvF2= M1TS[XNCVkeHUh?=
ARH-77 NIXtZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;kS2lEPTB;Mz60OlkyPSEQvF2= NGHiUoxUSU6JRWK=
NB17 NUXLWVMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nOXGlEPTB;Mz62N|g1PyEQvF2= NUjneGdyW0GQR1XS
A253 MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNwN{OyOFYh|ryP M{nQeXNCVkeHUh?=
OPM-2 MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTRRWZxUUN3ME20MlI4Pjh3IN88US=> MlTnV2FPT0WU
MV-4-11 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTRwM{[0OVQh|ryP MVHTRW5ITVJ?
SR NUfjOWpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX0NpVKSzVyPUSuOFk6PTRizszN M{L0e3NCVkeHUh?=
KG-1 MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID6[5RKSzVyPUSuOlA5PDVizszN NH3ROGJUSU6JRWK=
OCI-AML2 MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;x[ZdkUUN3ME21Mlg3OTV2IN88US=> MmDvV2FPT0WU
D-247MG MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\zb4JKSzVyPU[uNVI2OTlizszN M2G5cnNCVkeHUh?=
DJM-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXlTWM2OD14LkS4OVU5KM7:TR?= M3XkXXNCVkeHUh?=
RPMI-6666 M3qxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PkNWlEPTB;Nz6yO|A3PyEQvF2= NWi4fohmW0GQR1XS
KARPAS-45 Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXUOlFKSzVyPUeuOVE3PzFizszN MW\TRW5ITVJ?
LP-1 NF;IdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTdwNUS3PFIh|ryP MUnTRW5ITVJ?
RS4-11 NXi0cWJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[4bmtKSzVyPUeuOlU4QDdizszN M{\qOnNCVkeHUh?=
DU-4475 NHzrUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzBTWM2OD16LkKxOlUzKM7:TR?= NEjE[oZUSU6JRWK=
MONO-MAC-6 NFOwW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP4XWVKSzVyPUiuNlcxPjZizszN MmHiV2FPT0WU
NCI-SNU-16 NVzSUpptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW3cVVQUUN3ME24MlU3OTJ6IN88US=> MXnTRW5ITVJ?
SJSA-1 NF\jXJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3uxNGlEPTB;OD63NlgxPSEQvF2= MVTTRW5ITVJ?
MMAC-SF NGXB[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\VTWM2OD16Lke5N|A4KM7:TR?= NH;rc|dUSU6JRWK=
SK-NEP-1 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRThwOEmxOVUh|ryP NHHOc25USU6JRWK=
J-RT3-T3-5 MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Lob2lEPTB;OD65OlUzQSEQvF2= MnnPV2FPT0WU
SKM-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLRV3lKUUN3ME25MlAyPzN2IN88US=> NHuwbGlUSU6JRWK=
LB2241-RCC M1O1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkeyTWM2OD17LkCyNFEzKM7:TR?= MXPTRW5ITVJ?
SIG-M5 NGjXRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KyW2lEPTB;OT6wNlQ6OyEQvF2= NIjNRZdUSU6JRWK=
EVSA-T MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnqTWM2OD17LkK3O|k{KM7:TR?= M1;qR3NCVkeHUh?=
GT3TKB NYHGN|d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\tTWM2OD17LkO1OVQ3KM7:TR?= MX;TRW5ITVJ?
NB6 NXvlTYJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWGyO3dYUUN3ME25MlkzOjV7IN88US=> M2OxNHNCVkeHUh?=
EHEB NVjRTXJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFyLkC2OVYh|ryP MXfTRW5ITVJ?
HEL NHzw[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qwfGlEPTB;MUCuOFc4PiEQvF2= MX3TRW5ITVJ?
ALL-PO NEfyWY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDpXmpKSzVyPUGwMlc6OzhizszN NYjOZ4pQW0GQR1XS
TGW NYTZPFdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fNcGlEPTB;MUGuNlgzQCEQvF2= MYnTRW5ITVJ?
BC-3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DZfWlEPTB;MUKuNVE{QCEQvF2= NYfGUlhJW0GQR1XS
IA-LM NXjsfng1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrWTWM2OD1zMj60OFQ2KM7:TR?= NFnnfpJUSU6JRWK=
UACC-257 MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHaTWM2OD1zMj65NVk5KM7:TR?= MoX2V2FPT0WU
KP-N-YS MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTF{LkmyPFMh|ryP MUDTRW5ITVJ?
Raji MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL6b3ZKSzVyPUGzMlc1QTdizszN NWXNbFNDW0GQR1XS
SF539 M4T1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq3TWM2OD1zMz64OVU4KM7:TR?= MWDTRW5ITVJ?
DMS-153 NXLSVJJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fYNmlEPTB;MUSuNFAzQCEQvF2= M1;0PHNCVkeHUh?=
L-540 MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnT[29KSzVyPUG1MlA3PzJizszN M1LvOnNCVkeHUh?=
MN-60 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjHTWM2OD1zNT6xPVc6KM7:TR?= M3;zdXNCVkeHUh?=
RPMI-8866 NUDHOHM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDjXFBKSzVyPUG3MlQ1PTRizszN NYn5dHNjW0GQR1XS
NCI-H510A NHj4elZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF7LkO5O|Mh|ryP M3\oUnNCVkeHUh?=
NB13 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLNTWM2OD1zOT60PFc4KM7:TR?= NYTGeFdMW0GQR1XS
HAL-01 NHT4N2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XMd2lEPTB;MUmuO|U1OyEQvF2= Ml3lV2FPT0WU
NCI-H720 M3HNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jWXGlEPTB;MkCuNlc{OyEQvF2= MlLXV2FPT0WU
REH M3\ZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Szb2lEPTB;MkCuOlM2PyEQvF2= NFTwS3JUSU6JRWK=
KNS-81-FD NHzWTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor2TWM2OD1{Mz6xOFYh|ryP NH\rXndUSU6JRWK=
HC-1 NE\xN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJ2LkW1OVEh|ryP M3XwenNCVkeHUh?=
NCI-H2141 NUm0TnpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MontTWM2OD1{ND63O|U1KM7:TR?= NVz5e2Q6W0GQR1XS
MOLT-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJ4Lk[3OVMh|ryP MVHTRW5ITVJ?
OMC-1 NUnERpVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXjTWM2OD1{Nz6xOFIzKM7:TR?= M3TBbHNCVkeHUh?=
LC-1F Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu1PG5KUUN3ME2yO{4{OjR3IN88US=> NH2yboFUSU6JRWK=
NCI-H1304 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ6LkG2Nlgh|ryP NELySWZUSU6JRWK=
BC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\RUWlEPTB;MkiuOlUyKM7:TR?= MXTTRW5ITVJ?
NCI-H64 Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3frXWlEPTB;MkmuOlI2OyEQvF2= M2fPUHNCVkeHUh?=
MOLT-16 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmThTWM2OD1{OT62NlkzKM7:TR?= NFHyPZdUSU6JRWK=
U-87-MG M4TsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K1OGlEPTB;M{CuO|Y3KM7:TR?= NWrzXYJOW0GQR1XS
GAK M1PaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7JTWM2OD1|MT6yOlg3KM7:TR?= MnPLV2FPT0WU
ES8 NVXNbZR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTN{LkGyOVIh|ryP NXrTVHdsW0GQR1XS
HCC1599 M3\T[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTN{LkOzNlUh|ryP NGi1cXhUSU6JRWK=
EB-3 NHXqOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTN2LkOxNVch|ryP NYKzPIpyW0GQR1XS
HCC1187 NXToTY1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvUR4U5UUN3ME2zOU45ODV{IN88US=> MkDnV2FPT0WU
SK-PN-DW MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTN4LkG5OFMh|ryP NYjDZ5A5W0GQR1XS
JVM-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjG[pF1UUN3ME2zO{4zOzN6IN88US=> MoXxV2FPT0WU
HCC2157 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnHRW9KSzVyPUO3Mlk6PDZizszN NYO2Sm44W0GQR1XS
A4-Fuk MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki5TWM2OD1|OD6xNFA6KM7:TR?= NV2xcldNW0GQR1XS
COR-L279 NEXrbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfzOoE2UUN3ME20NE4zQDVzIN88US=> MoL0V2FPT0WU
DEL NG\HNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTRzLkmwPFYh|ryP M{TsXXNCVkeHUh?=
NCI-H1395 M4LZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvUem9pUUN3ME20Nk4xOTZ|IN88US=> MoTwV2FPT0WU
MHH-NB-11 NYS4SJk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknkTWM2OD12Mz6wPFE5KM7:TR?= M2XVT3NCVkeHUh?=
NCI-H2107 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rGUGlEPTB;NEOuOFg1PiEQvF2= NWfHeXR3W0GQR1XS
NEC8 NHrGUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTmTWM2OD12ND6zN|Yh|ryP Mn\jV2FPT0WU
COLO-684 M{\rWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fJXGlEPTB;NE[uNlI2QCEQvF2= M3SxUnNCVkeHUh?=
LS-411N M{PTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTR6LkS3OFgh|ryP M173eHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID